A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer
, , , , , , et
03 mars 2019
À propos de cet article
Catégorie d'article: Review
Publié en ligne: 03 mars 2019
Pages: 6 - 14
Reçu: 31 août 2018
Accepté: 05 janv. 2019
DOI: https://doi.org/10.2478/raon-2019-0006
Mots clés
© 2019 Li Ma, Yu Men, Lingling Feng, Jingjing Kang, Xin Sun, Meng Yuan, Wei Jiang, Zhouguang Hui published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.
Conclusions
Though effective dose-escalation methods have been explored, including altered fractionation, adapting individualized increments for different patients, and adopting new technologies and new equipment such as new radiation therapy, no consensus has been achieved yet.